Contineum Therapeutics shows meaningful analyst-implied upside and bullish above-200-day-MA momentum, but a quality score far below the engine's floor, modest insider selling, and its binary-outcome biotechnology profile keep the engine's stance at exit.
Thesis pillars
- Analyst Upside Valuation↓Deteriorating
- Quality Floor Exit Signal↓Deteriorating
- Overbought Momentum Risk↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Contineum Therapeutics, Inc. (CTNM) Stock Analysis
Oversold Bounce setup · Catalyst-Driven edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $8.56, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $322M below $400M minimum.
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation, and immunology, led by wholly-owned candidate PIPE-791, an LPA1 receptor antagonist in Phase 2 development for idiopathic pulmonary fibrosis.... Read more
Hold if already holding. Not a fresh buy at $8.56, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $322M below $400M minimum. Chart setup: Oversold RSI 28, near Bollinger lower, volume surge. Market cap $322M below $400M minimum. Not in investable universe. Score 5.4/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 16d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Contineum Therapeutics, Inc.
About Contineum Therapeutics, Inc.
Contineum Therapeutics' wholly-owned lead asset, PIPE-791, is a brain-penetrant LPA1 receptor antagonist advancing into a Phase 2 trial for idiopathic pulmonary fibrosis that began enrolling roughly 324 subjects in December 2025, alongside a completed Phase 1b trial in chronic pain with data expected in the second quarter of 2026. The clinical-stage biopharmaceutical company partners its second program, PIPE-307, a muscarinic M1 receptor antagonist renamed JNJ-89495120, with Johnson & Johnson, which reported $7.8 billion of neuroscience drug sales in 2025.
PIPE-791 targets the LPA1 receptor pathway implicated in pulmonary fibrosis, a mechanism the company says is clinically validated by third-party trials of other LPA1R antagonists, and Contineum is positioning the drug's once-daily dosing as a tolerability advantage over the three currently approved IPF therapies, which require multiple daily doses. PIPE-307 targets major depressive disorder and relapsing-remitting multiple sclerosis; J&J began its Phase 2 Moonlight-1 trial for MDD in December 2024 and retains sole discretion over whether to continue developing the molecule for either indication. Contineum deferred further clinical development of a separate PIPE-791 progressive multiple sclerosis program and its preclinical CTX-343 program in 2025 pending additional funding, concentrating near-term spending on the IPF and chronic pain indications.
Show full overview
Contineum's two-program structure carries asymmetric risk: PIPE-307's Phase 2 VISTA trial in relapsing-remitting multiple sclerosis, reported in November 2025, showed acceptable safety but missed both its primary and secondary efficacy endpoints, and J&J holds sole discretion over whether PIPE-307 advances further in RRMS, MDD, or any other indication. That leaves wholly-owned PIPE-791 as the more direct driver of company value, with the ongoing 26-week PROPEL-IPF trial measuring forced vital capacity as its primary efficacy endpoint against three already-approved competitors, including a nerandomilast product newly approved for U.S. marketing in 2025.
See also: Healthcare · Biotechnology
From Contineum Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-13Recent Developments — Contineum Therapeutics, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Monday's Intraday Session — benzinga Oct 12, 2026
- NEWS Why Is Contineum Therapeutics Stock Falling Monday? — benzinga Oct 12, 2026
- NEWS 12 Health Care Stocks Moving In Monday's Pre-Market Session — benzinga Oct 12, 2026
- NEWS Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday — benzinga Sep 30, 2026 neutral
- NEWS Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Lowers Price Target to $17 — benzinga Sep 28, 2026 negative
Generated 2026-10-13T11:42:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinePIPE-79110-K Item 1: 'Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor ("LPA1R") in development for idiopathic pulmonary fibrosis ("IPF") and chronic pain.'
- MEDIUMcounterpartyJohnson & Johnson (PIPE-307 partner)10-K Item 1: 'J&J has sole discretion whether or not to further develop PIPE-307 for RRMS, MDD, or any other indication.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.56, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $322M below $400M minimum. Chart setup: Oversold RSI 28, near Bollinger lower, volume surge. Market cap $322M below $400M minimum. Not in investable universe. Target $19.14 (+123.5%), stop $8.18 (−4.7%), A.R:R 8.2:1. Score 5.4/10, moderate confidence.
Take-profit target: $19.14 (+123.5% upside). Target $19.14 (+123.5%), stop $8.18 (−4.7%), A.R:R 8.2:1. Stop-loss: $8.18.
Concentration risk — Pipeline: PIPE-791; Market cap $322M below $400M minimum.
Contineum Therapeutics, Inc. trades at a P/E of N/A (forward -4.5). TrendMatrix value score: 9.0/10. Verdict: Hold.
14 analysts cover CTNM with a consensus score of 4.3/5. Average price target: $22.
What does Contineum Therapeutics, Inc. do?Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for...
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation, and immunology, led by wholly-owned candidate PIPE-791, an LPA1 receptor antagonist in Phase 2 development for idiopathic pulmonary fibrosis. Its partnered candidate PIPE-307, licensed to Johnson & Johnson as JNJ-89495120, missed the primary and secondary efficacy endpoints of a November 2025 Phase 2 trial in relapsing-remitting multiple sclerosis, though J&J continues a separate Phase 2 trial of the drug in major depressive disorder.